Evidence map›Paper›PMID 39186818›Full record

ReviewCanadian journal of physiology and pharmacology2024

Sarcopenia: recent advances for detection, progression, and metabolic alterations along with therapeutic targets.

Syeda Roohina Ali, Augustine T Nkembo, Srinivas M Tipparaju, Muhammad Ashraf, Wanling Xuan

Abstract readReview
In one paragraph

Review in Canadian journal of physiology and pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Protective Effects ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  4. Review
  5. Article
  6. Impact of probiotic, prebiotic, and synbiotic supplementation on the gut microbiome in older adults with sarcopenia, obesity, and sarcopenic obesity.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Review
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. The Role ofInternational journal of general medicine · 2025
    Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Syeda Roohina AliDepartment of Pharmaceutical Sciences, USF Health Taneja College of Pharmacy, University of South Florida, Tampa, FL, US.
Augustine T NkemboDepartment of Pharmaceutical Sciences, USF Health Taneja College of Pharmacy, University of South Florida, Tampa, FL, US.
Srinivas M TipparajuDepartment of Pharmaceutical Sciences, USF Health Taneja College of Pharmacy, University of South Florida, Tampa, FL, US.ORCID 0000-0002-2581-2502
Muhammad AshrafDepartment of Pharmaceutical Sciences, USF Health Taneja College of Pharmacy, University of South Florida, Tampa, FL, US.
Wanling XuanDepartment of Pharmaceutical Sciences, USF Health Taneja College of Pharmacy, University of South Florida, Tampa, FL, US.ORCID 0000-0002-5443-8994

Funding

Protecting the Diabetic Skeletal Muscle by Nampt ActivationR01DK119066 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI BROTTO, MARCO, TIPPARAJU, SRINIVAS M. · 2019 to 2023
$2.0M
hiPS cells derived skeletal muscle progenitors and their extracellular vesicles for treatment of sarcopeniaR01AG070145 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI XUAN, WANLING · 2021 to 2025
$1.8M
NIA NIH HHS R01 AG070145NIDDK NIH HHS R01 DK119066
6 · The paper itself

Abstract

Sarcopenia, a disorder marked by muscle loss and dysfunction, is a global health concern, particularly in aging populations. Sarcopenia is intricately related to various health conditions, including obesity, dysphagia, and frailty, which underscores the complexity. Despite recent advances in metabolomics and other omics data for early detection and treatment, the precise characterization and diagnosis of sarcopenia remains challenging. In the present review we provide an overview of the complex metabolic mechanisms that underlie sarcopenia, with particular emphasis on protein, lipid, carbohydrate, and bone metabolism. The review highlights the importance of leucine and other amino acids in promoting muscle protein synthesis and clarifies the critical role played by amino acid metabolism in preserving muscular health. In addition, the review provides insights regarding lipid metabolism on sarcopenia, with an emphasis on the effects of inflammation and insulin resistance. The development of sarcopenia is largely influenced by insulin resistance, especially with regard to glucose metabolism. Overall, the review emphasizes the complex relationship between bone and muscle health by highlighting the interaction between sarcopenia and bone metabolism. Furthermore, the review outlines various therapeutic approaches and potential biomarkers for diagnosing sarcopenia. These include pharmacological strategies such as hormone replacement therapy and anabolic steroids as well as lifestyle modifications such as exercise, nutrition, and dietary changes.

Indexed as

SarcopeniaAnimalsBiomarkersBone and BonesDisease ProgressionHumansInsulin ResistanceLipid MetabolismMuscle, SkeletalBiomarkersagingbiomarkerexercisemetabolismsarcopenia

Identifiers

PMID39186818
PMCPMC11663012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.